Walker R A
Department of Cancer Studies and Molecular Medicine, Leicester Royal Infirmary, Leicester, UK.
Histopathology. 2006 Oct;49(4):406-10. doi: 10.1111/j.1365-2559.2006.02514.x.
Immunohistochemistry is no longer a technique used only for research but is employed increasingly for diagnosis and for the assessment of therapeutic biomarkers. The latter, in particular, often require a semiquantitative evaluation of the extent of their presence. There are many factors that can affect this that relate to the method: fixation of tissue, duration and type of antigen retrieval, antibody specificity, antibody dilution and detection systems. Other complexities relate to assessment. Different scoring systems are used for either the same or different antigens. Cut-off levels for assessing whether a tissue is 'positive' or 'negative' can vary for the same antigen. Whilst there are quality assurance schemes for the methodology that have improved standards of staining, there are no similar schemes that relate to interpretation, although errors here can create as many problems. There have been improvements in automated analysis but availability is limited and it is still predominantly a research tool. In order for quantification of immunohistochemistry to be a reliable and reputable tool, there must be easy to use, reproducible, standardized protocols for assessment which are international. Improvements in automated analysis with wider applicability could lead to standardization.
免疫组织化学不再仅仅是一种用于研究的技术,而是越来越多地用于诊断和治疗生物标志物的评估。特别是后者,往往需要对其存在程度进行半定量评估。有许多与方法相关的因素会影响这一评估:组织固定、抗原修复的持续时间和类型、抗体特异性、抗体稀释和检测系统。其他复杂因素与评估有关。相同或不同的抗原会使用不同的评分系统。对于同一抗原,评估组织是“阳性”还是“阴性”的临界值可能会有所不同。虽然针对该方法的质量保证计划提高了染色标准,但对于解读却没有类似的计划,尽管此处的错误可能会引发同样多的问题。自动分析已有改进,但可用性有限,它仍然主要是一种研究工具。为了使免疫组织化学定量成为一种可靠且受认可的工具,必须有易于使用、可重复、标准化的国际评估方案。具有更广泛适用性的自动分析改进可能会带来标准化。